JP2011529683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529683A5 JP2011529683A5 JP2011504270A JP2011504270A JP2011529683A5 JP 2011529683 A5 JP2011529683 A5 JP 2011529683A5 JP 2011504270 A JP2011504270 A JP 2011504270A JP 2011504270 A JP2011504270 A JP 2011504270A JP 2011529683 A5 JP2011529683 A5 JP 2011529683A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- peptide
- antigen
- hla
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 16
- 150000001413 amino acids Chemical group 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 210000001808 exosome Anatomy 0.000 claims description 7
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8566308P | 2008-08-01 | 2008-08-01 | |
| US61/085,663 | 2008-08-01 | ||
| PCT/JP2009/003630 WO2010013485A1 (en) | 2008-08-01 | 2009-07-30 | Melk epitope peptides and vaccines containing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529683A JP2011529683A (ja) | 2011-12-15 |
| JP2011529683A5 true JP2011529683A5 (https=) | 2012-09-13 |
| JP5816918B2 JP5816918B2 (ja) | 2015-11-18 |
Family
ID=41610195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011504270A Active JP5816918B2 (ja) | 2008-08-01 | 2009-07-30 | Ｍｅｌｋエピトープペプチドおよびそれを含むワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8674069B2 (https=) |
| EP (1) | EP2321411B1 (https=) |
| JP (1) | JP5816918B2 (https=) |
| KR (1) | KR101705514B1 (https=) |
| CN (1) | CN102171340B (https=) |
| AU (1) | AU2009277811B2 (https=) |
| BR (1) | BRPI0916940A2 (https=) |
| CA (1) | CA2732721A1 (https=) |
| DK (1) | DK2321411T3 (https=) |
| ES (1) | ES2572367T3 (https=) |
| IL (2) | IL210861A (https=) |
| MX (1) | MX2011001194A (https=) |
| SG (1) | SG193161A1 (https=) |
| TW (1) | TWI466680B (https=) |
| WO (1) | WO2010013485A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI466680B (zh) | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗 |
| TWI485245B (zh) * | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗 |
| SG11201405578TA (en) | 2012-03-09 | 2014-11-27 | Oncotherapy Science Inc | Pharmaceutical composition containing peptide |
| PT106590B (pt) | 2012-10-22 | 2015-01-20 | Secil S A Companhia Geral De Cal E Cimento S A | Mistura cimentícia branca ou colorida para fabrico de betão, argamassa e pastas interactivas, com propriedades fotoluminescentes |
| CN106117337B (zh) * | 2016-06-24 | 2020-02-11 | 安徽未名细胞治疗有限公司 | 一种特异性肿瘤抗原sf的ctl识别表位肽及其应用 |
| KR102579047B1 (ko) | 2016-08-31 | 2023-09-14 | 온코세라피 사이언스 가부시키가이샤 | MELK에 대한 단클론 항체(monoclonal antibody) 및 그 사용 |
| KR102614437B1 (ko) * | 2021-02-03 | 2023-12-14 | 충북대학교 산학협력단 | 중년 남성 특이적 비만 또는 대사질환의 치료제로서 ｍｐｋ３８／ｍｅｌｋ의 신규 용도 |
| CN121064280A (zh) * | 2024-06-04 | 2025-12-05 | 复旦大学附属中山医院 | 一种抗肝癌hla-a*02型疫苗及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100209784B1 (ko) | 1996-10-08 | 1999-07-15 | 박원훈 | 인간 단백질 변이인산화효소 유전자(hpk 38), 그의 염기 서열, 효소 단백질 및 그의 아미노산 서열 |
| US6229001B1 (en) * | 1997-01-03 | 2001-05-08 | Southern Research Institute | Mycobacterium fol a gene that encodes for the enzyme dihydrofolate reductase |
| US6605709B1 (en) * | 1999-04-09 | 2003-08-12 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics |
| ES2299493T3 (es) * | 2000-05-31 | 2008-06-01 | Novartis Vaccines And Diagnostics, Inc. | Composiciones y metodos para tratar la enfermedad neoplasica usando sensibilizadores a la radiacion y a la quimioterapia. |
| US6833447B1 (en) * | 2000-07-10 | 2004-12-21 | Monsanto Technology, Llc | Myxococcus xanthus genome sequences and uses thereof |
| US20020156263A1 (en) * | 2000-10-05 | 2002-10-24 | Huei-Mei Chen | Genes expressed in breast cancer |
| GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| US20030157082A1 (en) | 2002-01-31 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules |
| US7547534B2 (en) * | 2002-06-14 | 2009-06-16 | Verenium Corporation | Methods for making a composition to treat a wood, a pulp or a paper |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| WO2004070062A2 (en) | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| ES2609234T3 (es) | 2003-06-24 | 2017-04-19 | Genomic Health, Inc. | Predicción de la probabilidad de recidiva de cáncer |
| WO2005016279A2 (en) | 2003-08-14 | 2005-02-24 | Exelixis, Inc. | Melks as modifiers of the rac pathway and methods of use |
| JP4721903B2 (ja) * | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | 新規腫瘍抗原蛋白質及びその利用 |
| DE602005025231D1 (de) | 2004-08-10 | 2011-01-20 | Oncotherapy Science Inc | Gene und polypeptide in verbindung mit brustkrebserkrankungen |
| US7915036B2 (en) * | 2004-09-13 | 2011-03-29 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising T cell receptors and methods of use thereof |
| EP1856278A2 (en) * | 2005-02-10 | 2007-11-21 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| US8088976B2 (en) * | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| US20090075832A1 (en) * | 2005-02-24 | 2009-03-19 | Cemines, Inc | Compositions and Methods for Classifying Biological Samples |
| CN101283106A (zh) | 2005-07-27 | 2008-10-08 | 肿瘤疗法科学股份有限公司 | 小细胞肺癌的诊断方法 |
| CN101287831B (zh) * | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| WO2008023841A1 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Breast cancer-associated gene, melk, and its interactions with bcl-g |
| TWI466680B (zh) | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗 |
-
2009
- 2009-07-29 TW TW98125493A patent/TWI466680B/zh not_active IP Right Cessation
- 2009-07-30 EP EP09802730.3A patent/EP2321411B1/en active Active
- 2009-07-30 ES ES09802730T patent/ES2572367T3/es active Active
- 2009-07-30 CA CA2732721A patent/CA2732721A1/en not_active Abandoned
- 2009-07-30 WO PCT/JP2009/003630 patent/WO2010013485A1/en not_active Ceased
- 2009-07-30 KR KR1020117004323A patent/KR101705514B1/ko not_active Expired - Fee Related
- 2009-07-30 DK DK09802730.3T patent/DK2321411T3/en active
- 2009-07-30 US US13/056,598 patent/US8674069B2/en active Active
- 2009-07-30 SG SG2013057914A patent/SG193161A1/en unknown
- 2009-07-30 JP JP2011504270A patent/JP5816918B2/ja active Active
- 2009-07-30 CN CN200980138900.XA patent/CN102171340B/zh active Active
- 2009-07-30 AU AU2009277811A patent/AU2009277811B2/en not_active Ceased
- 2009-07-30 MX MX2011001194A patent/MX2011001194A/es active IP Right Grant
- 2009-07-30 BR BRPI0916940A patent/BRPI0916940A2/pt not_active IP Right Cessation
-
2011
- 2011-01-25 IL IL210861A patent/IL210861A/en not_active IP Right Cessation
-
2014
- 2014-02-03 US US14/171,532 patent/US9193765B2/en active Active
- 2014-05-05 IL IL232461A patent/IL232461A0/en unknown
-
2015
- 2015-10-27 US US14/924,546 patent/US9675680B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500001A5 (https=) | ||
| RU2011110504A (ru) | Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды | |
| JP2010506826A5 (https=) | ||
| JP2010523471A5 (https=) | ||
| JP2011529683A5 (https=) | ||
| JP2010519176A5 (https=) | ||
| JP2012517799A5 (https=) | ||
| JP2011524737A5 (https=) | ||
| RU2009141595A (ru) | Пептиды тем8 и содержащие их вакцины | |
| HRP20141233T1 (hr) | PEPTIDNA CJEPIVA DOBIVENA IZ EphA4 | |
| RU2009118432A (ru) | Пептидные вакцины против рака с экспрессией полипептидов mphosph1 или depdc1 | |
| JP2008530975A5 (https=) | ||
| JP2013511958A5 (https=) | ||
| RU2011138160A (ru) | Пептиды foxmi и вакцины, содержащие их | |
| JP2012500184A5 (https=) | ||
| RU2010154081A (ru) | Эпитопные пептиды iqgap3 вакцины, содержащие их | |
| RU2012127358A (ru) | Олигопептиды imp-3 и содержащие их вакцины | |
| JP2016511221A5 (https=) | ||
| JP2012520659A5 (https=) | ||
| JP2019537562A5 (https=) | ||
| JP2013517764A5 (https=) | ||
| JP2014533095A5 (https=) | ||
| JP2013523084A5 (https=) | ||
| JP2015529219A5 (https=) | ||
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины |